By the Numbers: Our Response to COVID-19

We are honored to support a resilient research community during the COVID-19 pandemic. See the data points below, watch the video, and download our info sheet to find out how Advarra helps keep research moving forward.

Download a larger version of the infographic

Advarra’s COVID-19 Response by the Numbers

IRB and IBC Support

• 100% Operation Warp Speed Vaccine Trials supported by Advarra’s IRB and IBC
• IRB reviewed 429 COVID-19 protocols across over 2,500 sites
• IBC reviewed 76 COVID-19 submissions
• First COVID-19 protocol submission received: 2/11/20
• Reviews conducted for Phase I-IV plus observational data and collection research
• Free transfers of IRB oversight to keep research moving despite pandemic restrictions: 116 studies, over 500 sites
• IRB average turnaround from submission to review: 1-2 business days
• IBC average turnaround from submission to review: 4-5 business days

Research Administration Support

• Remote audits conducted worldwide: 125 across 5 continents
• Staff augmentation: 20+ experts deployed to support organizations, some in response to layoffs & furloughs
• COVID study calendars built for OnCore customers: 179
• Average study calendar turnaround time: 1 business day
• Advarra eRegulatory management system: supported 3,187 users; 239,435 documents; 84,752 signatures; 1,100 review sessions; 1,804 protocols

Free Educational Resources

• COVID-related webinars and virtual events: 9 and reached 15,000+ research professionals
• eLearning tool downloads: 669
• COVID-centric blog posts: 21

Ask Advarra

Launched March 16, 2020, Ask The Experts was the first free source for direct information on IRB, IBC, and regulatory concerns related to COVID-19 and research.

• Target time from question submission to response: 24 hours
• Questions answered same day as submission: 90%
• Questions answered: 655 and counting

Coronavirus Guidance

Our Coronavirus Guidance webpages provide timely information and explanations about pandemic-related research changes, regulatory guidance updates, and other critical resources. Popular questions from Ask Advarra are posted to the Coronavirus Guidance so that all may benefit.

• Research professionals helped: over 20,500
• Subscribers to weekly email updates: 425
• Frequency of updates: weekly
• Versions of Advarra’s Coronavirus Guidance Page: 22
• Email updates sent: Approximately 7,000
• Topics covered: 30
• Worldwide regulatory and other resources cited: 16
  • ­­­FDA
  • Health Canada
  • AEMPS
  • HMA
  • HHS
  • OCR
  • MHRA
  • NCI
  • VA
  • Agency of Medicines
  • EMA
  • EC
  • PRIM&R
  • Agenzia Italiana del Farmaco
  • CITI
  • BBK

Data accurate as of October 2020.

Back to Resources